|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Roche Holding Ltd - SWOT Analysis |
|
|
|
|
€ 100,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Mars 2008 |
Taille du document : |
32 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Pharmaceutical industry in the 21st Century
150 pages | Octobre 1998 |
Does the 21st century herald the beginning of a genomics revolution? Which disease areas will provide the greatest growth potential and why? Which technologies have the greatest potential to max |
795,00 €
|
| |
| |
Pfizer's Recent Takeover
15 pages | Juillet 2002 |
On 15th July 2002, Pfizer announced the acquisition of Pharmacia in a stock-for-stock transaction valued at $60 billion, expanding the company's core strengths in pharmaceuticals and health care.
|
300,00 €
|
| |
| |
The Pharmacogenomics Outlook
174 pages | Août 2000 |
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differenc |
955,00 €
|
| |
| |
OTC Cough and Cold Remedies in Germany
15 pages | Juillet 2002 |
The German market for OTC cough and cold remedies reached a value of Euro 972 million (US$ 918 million) in 2001, up 0.4% on the previous year.
During the review period, the market grew by 9.4%, an |
198,00 €
|
| |
| |
OTC Analgesics in Germany
15 pages | Juillet 2002 |
The German market for OTC analgesics growth not so rapidly and reached a value of Euro 772 million (US$ 729 million) in 2001, an increase of 1.6% on the previous year.
Over the review period, the m |
198,00 €
|
| |
| |
Chinese Markets for Pharmaceuticals
225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic |
3 500,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Antisense Therapy: Technical Aspects and Commercial Opportunities
334 pages | Mars 2000 |
Antisense therapy interferes with the expression of disease-causing proteins, thus offering a direct and selective intervention in the disease process.
Besides the well known oligonucleotides ( |
955,00 €
|
| |
| |
Healthcare: Germany
106 pages | Octobre 2000 |
Compare the changes in expenditure between the different healthcare sectors in Germany · Understand the main factors affecting demand for healthcare services in Germany · Examine the |
578,54 €
|
| |
| |
Patient Power Outlook 2001
152 pages | Juillet 2001 |
The increase in patient power witnessed over the last decade has been driven by developments in healthcare systems, patient advocacy activity, the increasing influence of the media in healthcare issue |
955,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Roche Holding Ltd - SWOT Analysis |
|
|
Datamonitor's Roche Holding Ltd - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Roche Holding, a holding company, is one of the leading research-focused healthcare groups in the world. The group specializes in the discovery, development and commercialization of therapeutics for life-threatening diseases, including cancer. The group operates across the world through its subsidiaries and partners, including majority ownership interests in Genentech and Chugai. It is headquartered in Basel, Switzerland and employs about 74,400 people. The group recorded revenues of CHF42 billion (approximately $34.5 billion) during the fiscal year ended December 2006, an increase of 18.4% over 2005. The operating profit of the group was CHF11.7 billion (approximately $9.6 billion) during fiscal year 2006, an increase of 35.3% over 2005. The net profit was CHF9.2 billion (approximately $7.5 billion) in fiscal year 2006, an increase of 36.3% over 2005.
Scope of the Report
- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement
Reasons to Purchase
- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available
|
|
Table of Contents:
This product typically includes the following sections:
Key Facts
Company Overview
Business Description
Company History
Key Employees
Key Employee Biographies
Company View
SWOT analysis
Products & Services Listing
Products & Services Analysis
|
|
|
PPLSEN
|
|
|
|
|
